GlassScriptPhysician profile
Aaron John Harris
NPI 1770858144
$14,655.75
in general payments reported to CMS, 2019-2025
62 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $3,058 · 2023: $4,662 · 2024: $4,235 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $51.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,281.59 |
| Education | $51.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,232.57 | 2022-2025 | |
| Gilead Sciences, INC. | $839.03 | 2022-2025 | Trodelvy |
| Lilly USA, LLC | $762.64 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Astrazeneca Pharmaceuticals LP | $619.66 | 2021-2025 | Enhertu, Imfinzi, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $600.52 | 2022-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Celgene Corporation | $556.79 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $554.87 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $535.90 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $517.88 | 2022-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $470.20 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Eisai INC. | $458.24 | 2022-2025 | |
| Genzyme Corporation | $436.38 | 2021-2025 | |
| Glaxosmithkline, LLC. | $425.33 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Incyte Corporation | $406.10 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Exelixis INC. | $395.95 | 2022-2025 | Cabometyx |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $366.70 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Genentech USA, INC. | $362.72 | 2022-2024 | Perjeta, Phesgo, Tecentriq |
| Amgen INC. | $330.70 | 2021-2023 | Kyprolis, Blincyto, Lumakras |
| Alexion Pharmaceuticals, INC. | $319.64 | 2022-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $311.60 | 2021-2025 | Opdivo, Opdualag |
| Abbvie INC. | $305.69 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $270.16 | 2023-2025 | Libtayo, Eylea Hd |
| Beigene USA, INC. | $253.17 | 2022-2025 | Brukinsa |
| Taiho Oncology, INC. | $236.94 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $216.17 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Stemline Therapeutics INC. | $190.45 | 2023-2025 | Orserdu |
| Caris Mpi, INC. | $188.49 | 2025 | Mi Cancer Seek |
| Jazz Pharmaceuticals INC. | $157.73 | 2022-2024 | |
| Tempus Ai, INC | $150.23 | 2024-2025 | Xt Cdx |
| Janssen Pharmaceuticals, INC | $136.65 | 2022-2024 | Xarelto |
| Morphosys, US INC. | $133.81 | 2022-2023 | Monjuvi |
| Pharmacosmos Therapeutics INC. | $129.43 | 2022-2025 | Monoferric, Cosela |
| Mirati Therapeutics, INC. | $126.36 | 2023-2024 | Krazati |
| Blueprint Medicines Corporation | $121.96 | 2022-2025 | Ayvakit |
| Servier Pharmaceuticals LLC | $120.37 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.84 | 2022-2025 | |
| Genmab U.S., INC. | $119.00 | 2023-2025 | Epkinly |
| Kyowa Kirin, INC. | $106.83 | 2022-2023 | Poteligeo |
| Puma Biotechnology, INC. | $97.08 | 2021-2023 | |
| Coherus Oncology, INC. | $95.39 | 2022-2025 | Loqtorzi |
| Sobi, INC | $92.00 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $88.58 | 2022-2025 | Xpovio |
| Secura Bio, INC. | $74.15 | 2022-2024 | Copiktra |
| Springworks Therapeutics, INC. | $73.72 | 2024-2025 | Ogsiveo, Gomekli |
| Allergan, INC. | $66.12 | 2021 | |
| Tersera Therapeutics LLC | $62.35 | 2023-2024 | Zoladex, Xermelo |
| Array Biopharma INC | $47.37 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Aveo Pharmaceuticals, INC. | $36.99 | 2022 | |
| Emd Serono, INC. | $32.95 | 2023-2024 | Tepmetko |
| Adaptive Biotechnologies Corporation | $29.93 | 2023 | Clonoseq |
| Mylan Institutional INC. | $29.90 | 2022-2023 | Ogivri |
| Sumitomo Pharma America, INC. | $29.33 | 2023 | Orgovyx |
| Kite Pharma, INC. | $28.96 | 2023-2024 | Yescarta |
| Astellas Pharma US INC | $28.17 | 2024-2025 | Padcev, Xospata |
| Shield Therapeutics INC | $23.70 | 2024 | |
| Azurity Pharmaceuticals, INC. | $22.81 | 2025 | Danziten |
| Spectrum Pharmaceuticals INC. | $22.45 | 2024 | Rolvedon |
| Novo Nordisk INC | $21.29 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $20.24 | 2023 | Imbruvica |
| Dova Pharmaceuticals | $16.77 | 2021 | |
| Agios Pharmaceuticals, INC. | $14.85 | 2022 | |
| Apellis Pharmaceuticals, INC. | $13.95 | 2023 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.